• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis.使用mFOLFOX6联合帕尼单抗对伴有家族性腺瘤性息肉病的多发性结直肠癌不可切除肝转移进行转化治疗。
Int Surg. 2014 Nov-Dec;99(6):795-801. doi: 10.9738/INTSURG-D-13-00125.1.
2
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.PEAK：一项随机、多中心的 II 期研究，评估帕尼单抗联合改良氟尿嘧啶、亚叶酸钙和奥沙利铂（mFOLFOX6）或贝伐珠单抗联合 mFOLFOX6 治疗既往未经治疗、不可切除、野生型 KRAS 外显子 2 转移性结直肠癌患者的疗效。
J Clin Oncol. 2014 Jul 20;32(21):2240-7. doi: 10.1200/JCO.2013.53.2473. Epub 2014 Mar 31.
3
[Preoperative chemotherapy with modified FOLFOX + panitumumab for the treatment of descending colon cancer with multiple liver metastases - a case study].[改良FOLFOX方案联合帕尼单抗术前化疗治疗降结肠癌伴多发肝转移——病例报告]
Gan To Kagaku Ryoho. 2015 Jan;42(1):109-12.
4
[A Case of Simultaneous Laparoscopic Resection of Sigmoid Colon Cancer and Liver Metastases after Chemotherapy with Modified FOLFOX6 plus Panitumumab].[1例经改良FOLFOX6联合帕尼单抗化疗后同期腹腔镜切除乙状结肠癌及肝转移瘤的病例]
Gan To Kagaku Ryoho. 2015 Nov;42(12):2166-8.
5
[Therapeutic effect of mFOLFOX6 for synchronous unresectable liver metastases from colorectal cancer].mFOLFOX6方案治疗结直肠癌同时性不可切除肝转移的疗效
Gan To Kagaku Ryoho. 2011 Nov;38(12):2211-3.
6
[Long-Term Survival in a Case of Sigmoid Colon Cancer with Multiple Liver Metastases Treated with Repeated Hepatectomies].[乙状结肠癌伴多发肝转移经多次肝切除治疗后的长期生存]
Gan To Kagaku Ryoho. 2016 Nov;43(12):1736-1738.
7
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].[1例经改良FOLFOX6联合帕尼单抗诱导化疗后成功切除的晚期直肠癌病例]
Gan To Kagaku Ryoho. 2016 May;43(5):641-4.
8
[A case of resection of synchronous multiple liver metastases from colorectal cancer after FOLFOX chemotherapy].[1例FOLFOX化疗后同期切除结直肠癌多发肝转移灶的病例]
Gan To Kagaku Ryoho. 2009 Mar;36(3):501-4.
9
[A Case of Radical Resection of Rectal Cancer with Multiple Liver and Lung Metastases after Preoperative Chemotherapy].[1例术前化疗后直肠癌伴多发肝肺转移的根治性切除术病例]
Gan To Kagaku Ryoho. 2015 Oct;42(10):1274-6.
10
[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].[1例结直肠癌异时性多发肝转移经mFOLFOX+贝伐单抗化疗后达到病理完全缓解的病例]
Gan To Kagaku Ryoho. 2009 Nov;36(12):2166-8.

本文引用的文献

1
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.西妥昔单抗联合化疗作为 KRAS 野生型转移性结直肠癌的一线治疗：CRYSTAL 和 OPUS 随机临床试验的汇总分析。
Eur J Cancer. 2012 Jul;48(10):1466-75. doi: 10.1016/j.ejca.2012.02.057. Epub 2012 Mar 23.
2
Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.西妥昔单抗联合奥沙利铂一线治疗晚期结直肠癌的随机 3 期 MRC COIN 试验结果。
Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.
3
Evolution of neoadjuvant therapy for extended hepatic metastases--have we reached our (non-resectable) limit?新辅助治疗扩大肝转移的演变——我们是否已经达到（不可切除）极限？
J Surg Oncol. 2010 Dec 15;102(8):922-31. doi: 10.1002/jso.21727.
4
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.随机、III 期临床试验：帕尼单抗联合氟尿嘧啶、亚叶酸钙和奥沙利铂（FOLFOX4）对比 FOLFOX4 一线治疗未经治疗的转移性结直肠癌患者：PRIME 研究。
J Clin Oncol. 2010 Nov 1;28(31):4697-705. doi: 10.1200/JCO.2009.27.4860. Epub 2010 Oct 4.
5
Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials.结直肠癌肝转移的术前化疗：近期临床试验更新。
Cancer Chemother Pharmacol. 2010 Jul;66(2):209-18. doi: 10.1007/s00280-010-1297-x. Epub 2010 Mar 24.
6
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.西妥昔单抗与化疗联合作为转移性结直肠癌的初始治疗方案
N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.
7
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.结直肠癌中的PIK3CA突变与对表皮生长因子受体（EGFR）靶向单克隆抗体的临床耐药性相关。
Cancer Res. 2009 Mar 1;69(5):1851-7. doi: 10.1158/0008-5472.CAN-08-2466. Epub 2009 Feb 17.
8
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer.氟尿嘧啶、亚叶酸钙以及奥沙利铂联合或不联合西妥昔单抗用于转移性结直肠癌的一线治疗。
J Clin Oncol. 2009 Feb 10;27(5):663-71. doi: 10.1200/JCO.2008.20.8397. Epub 2008 Dec 29.
9
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.野生型BRAF是转移性结直肠癌对帕尼单抗或西妥昔单抗产生反应所必需的。
J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.
10
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.K-ras突变与晚期结直肠癌患者从西妥昔单抗治疗中获益的关系
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

使用mFOLFOX6联合帕尼单抗对伴有家族性腺瘤性息肉病的多发性结直肠癌不可切除肝转移进行转化治疗。

Conversion Therapy Using mFOLFOX6 With Panitumumab for Unresectable Liver Metastases From Multiple Colorectal Cancers With Familial Adenomatous Polyposis.

作者信息

Toiyama Yuji, Inoue Yasuhiro, Kitajima Takahito, Okigami Masato, Kawamura Mikio, Kawamoto Aya, Okugawa Yoshinaga, Hiro Jyunichiro, Tanaka Koji, Mohri Yasuhiko, Kusunoki Masato

机构信息

Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Graduate School of Medicine, Mie University, Mie, Japan.

出版信息

Int Surg. 2014 Nov-Dec;99(6):795-801. doi: 10.9738/INTSURG-D-13-00125.1.

DOI:10.9738/INTSURG-D-13-00125.1
PMID:25437589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4254242/
Abstract

A 39-year-old man received a diagnosis of unresectable multiple liver metastases from multiple colorectal cancers with familial adenomatous polyposis. After construction of an ileostomy, modified FOLFOX6 (mFOLFOX6) with panitumumab was administrated because rectal cancer and sigmoid colon cancer are KRAS wild type. The 13 courses of chemotherapy resulted in a marked reduction in the size of liver metastases and sigmoid colon cancer. Consequently, curative resection with total colectomy, ileal pouch anal anastomosis, and liver metastasis resection with radiofrequency ablation was performed. Progression of KRAS wild-type rectal cancer after chemotherapy suggested that each clone from rectal and sigmoid colon cancer might have a different sensitivity to epidermal growth factor receptor antibody. Immunohistochemical analysis revealed loss of PTEN expression in rectal cancer compared with liver metastases from sigmoid colon cancer, showing that the difference of mFOLFOX6 with panitumumab might be related to activation of the PI3K-AKT pathway.

摘要

一名39岁男性被诊断为患有家族性腺瘤性息肉病的多发性结直肠癌伴不可切除的多发性肝转移。在进行回肠造口术后，由于直肠癌和乙状结肠癌为KRAS野生型，给予了联合帕尼单抗的改良FOLFOX6（mFOLFOX6）方案化疗。13个疗程的化疗使肝转移灶和乙状结肠癌的大小显著缩小。因此，进行了全结肠切除术、回肠储袋肛管吻合术及肝转移灶射频消融根治性切除术。化疗后KRAS野生型直肠癌进展提示，直肠癌和乙状结肠癌的每个克隆对表皮生长因子受体抗体可能具有不同的敏感性。免疫组化分析显示，与乙状结肠癌肝转移灶相比，直肠癌中PTEN表达缺失，表明mFOLFOX6联合帕尼单抗的差异可能与PI3K-AKT通路的激活有关。